Freenome Appoints Linh H. Le as Chief Financial Officer
Seasoned diagnostics executive brings expertise in financial strategy and operational infrastructure development across diagnostics and Medtech industries
BRISBANE, Calif., May 21, 2025 /PRNewswire/ -- Freenome, a biotechnology company pioneering an early cancer detection platform, today announced the appointment of Linh H. Le as its new chief financial officer. Linh brings more than two decades of experience in leading finance and operations across diagnostics and Medtech companies, including Ambry Genetics, Medtronic and Predicine. At Freenome, Linh will oversee financial strategy and operational execution, supporting the company as it expands its commercial footprint.
'Linh has a proven track record of building the financial and operational foundations required to scale and sustain innovation,' said Aaron Elliott, Ph.D., chief executive officer of Freenome. 'He has led large-scale transformations, improved enterprise performance, and brings a focused, results-oriented approach that will help us execute with precision and purpose. I'm thrilled to welcome him to Freenome's leadership team.'
Prior to joining Freenome, Linh served as CFO at Predicine, where he implemented a best-in-class revenue cycle management system and led expansion into multiple U.S. markets. He previously held the role of chief operating officer at Ambry Genetics, where he led organization-wide change that supported significant sample volume growth and operational scalability. Earlier in his career, Linh spent 14 years at Medtronic Diabetes, where he served as CFO for the intensive insulin management business unit with oversight across North America, EMEA, and Asia-Pacific.
Linh began his career in assurance practice at KPMG and management advisory practice at PwC before taking on leadership roles at The Walt Disney Company and Fox. He is a Certified Public Accountant, holds a Bachelor of Science in Business Administration and Accounting from California State University, Northridge, and completed executive coursework at the Wharton School of Business. He was named CFO of the Year by the Los Angeles Times in 2022.
About Freenome
Freenome is breaking barriers to early cancer detection with a suite of blood tests built on its multiomics platform. The company recognizes that no single technology can identify every cancer due to the disease's inherent heterogeneity. Freenome's multimodal approach combines molecular biology and assays with computational biology, machine learning and multiple data types to tune into cancer's subtlest cues, even at the earliest stages of the disease.
With the convenience of a standard blood draw, Freenome aims to empower everyone to access recommended cancer screenings. The company is partnering with healthcare organizations and population health decision-makers to integrate its technology and software platform, making cancer detection easier and more accessible. Freenome is headquartered in Brisbane, California. Find out more at www.freenome.com and visit us on LinkedIn.
View original content to download multimedia: https://www.prnewswire.com/news-releases/freenome-appoints-linh-h-le-as-chief-financial-officer-302461231.html
SOURCE Freenome Holdings, Inc.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Entrepreneur
2 days ago
- Entrepreneur
HealthKois Launches USD 300 Mn Healthcare-Focused Fund
Over the next four years, the firm aims to invest between USD 7 million to USD 25 million per company in early growth-stage businesses operating across healthtech, life sciences, medtech, healthcare delivery and climate health. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. In a major boost to India's healthcare investment landscape, HealthKois, a new healthcare-focused investment firm, has been launched with a target corpus of USD 300 million and an additional USD 100 million green shoe option. Spearheaded by the leadership team behind HealthQuad—Charles Janssen (Managing Partner), Ajay Mahipal (Partner), and Dr Pinak Shrikhande (Partner)—the firm aims to accelerate healthcare transformation through strategic investments in high-impact, technology-driven enterprises. As the successor fund to HealthQuad, HealthKois is set to invest between USD 7 million and USD 25 million per company over the next four years. The focus will be on early growth-stage businesses across healthtech, life sciences, medtech, healthcare delivery, and climate health sectors. The goal is to support ventures that deliver both robust clinical outcomes and sustainable infrastructure solutions. "HealthKois will back technology-led and innovative healthcare companies that address critical gaps in accessibility, affordability, and quality of care," said Charles Janssen. "With access to over 75% proprietary deal flow, we're well-positioned to leverage our deep networks and operational expertise to deliver both superior financial returns and societal outcomes." "HealthKois represents our deep belief that meaningful change in healthcare can only be achieved by scaling enterprises that blend purpose with performance," said Ajay Mahipal. "We're not just capital providers—we're long-term collaborators with founders, bringing strategic insight and sector knowledge to help unlock their full potential." Dr Pinak Shrikhande added, "Our experience has taught us that true innovation in healthcare is born out of empathy, evidence, and execution. We look for companies that go beyond intent to deliver real clinical and operational impact." HealthKois builds on the legacy of HealthQuad Funds I and II, which have collectively touched over 90 million lives and serve more than 8 million patients annually. While the earlier funds will continue under their current framework, HealthKois signals a new chapter in advancing healthcare innovation across India and other low- and middle-income countries.
Yahoo
2 days ago
- Yahoo
MEDevice Boston Unveils Expanded Features for 2025 Event
BOSTON, MA / / June 5, 2025 / MEDevice Boston, the premier event for medical device professionals in New England (September 30-October 1 at the Boston Convention Center, Boston), announces an extensive lineup of new features for its upcoming conference and exhibition. Under the theme "Engineered to Advance," the event will deliver curated insights, strategic connections and meaningful opportunities specifically designed to propel careers and businesses forward at the heart of New England's MedTech hub. The revamped slate is centered on enhancing engagement and intentional opportunities for meaningful interaction. From peer-to-peer learning spaces to dynamic networking formats, every addition is crafted to maximize value, spark innovation and create lasting relationships within the MedTech community, particularly in Boston, which leads the nation in aggregate employment with more than 40,000 professionals and stands as one of its most vibrant innovation ecosystems. New Show Floor Features Include: Enhanced Conference Program: Expert-led sessions designed to tackle today's key challenges and opportunities in MedTech. Hands-On Workshops: Interactive sessions where MedTech professionals can turn ideas into action under expert guidance. Quick-Connect: High-energy, time-efficient networking designed to spark meaningful connections in minutes. Expanded Networking Opportunities: Daily roundtable discussions, themed show floor tours and welcome receptions. Innovation Center: A dedicated space to experience the latest innovations through live device simulations and hands-on exploration. Fireside Chats: A candid forum where MedTech leaders share real stories, bold insights and future-focused ideas. Innovation Spotlight Theater: Live, dynamic presentations from suppliers showcasing cutting-edge technology. Leaders in MedTech Program: Exclusive opportunities to connect with peers from startups to the top 40 OEMs in the New England region. The Franklin Visionary Awards Luncheon: Prestigious recognition for breakthrough technologies combined with high-level networking. "Medical device professionals cannot afford to waste time," says Melissa Magestro, Vice President, Informa Markets Engineering. "They are looking for solutions to their specific needs so they can advance themselves, their businesses, the industry and ultimately, patient care worldwide. We have engineered our entire event experience specifically to advance the medical device industry and the people and businesses that serve it." With the expanded features and renewed focus on valuable engagement, MEDevice Boston remains a trusted touchpoint for staying ahead of the curve. Whether attendees are seeking insight into emerging technologies, strategic guidance or a space to showcase advancements, the 2025 edition promises to deliver tangible value and fresh perspective in a constantly shifting MedTech landscape. Registration for MEDevice Boston 2025 is now open, please visit: About Informa Markets Engineering Informa Markets Engineering, a subsidiary of Informa plc (LON:INF), portfolio is the leading B2B event producer, publisher, and digital media business for the world's $3-trillion advanced, technology-based manufacturing industry. Our print and electronic products deliver trusted information to the engineering market and leverage our proprietary 1.3-million-name database to connect suppliers with buyers and purchase influencers. We produce more than 50 events and conferences in a dozen countries, connecting manufacturing professionals from around the globe. The Engineering portfolio is organized by Informa, the world's leading exhibitions organizer that brings a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, please visit Media Contact Informa Markets EngineeringEngineeringPR@ SOURCE: INFORMA MARKETS - ENGINEERING View the original press release on ACCESS Newswire
Yahoo
3 days ago
- Yahoo
SetPoint Medical Appoints Tyler Binney to Its Board of Directors
VALENCIA, Calif., June 04, 2025--(BUSINESS WIRE)--SetPoint Medical, a clinical-stage healthcare company dedicated to people living with chronic autoimmune diseases, today announced the appointment of Tyler Binney to its Board of Directors. With a career built around scaling disruptive MedTech platforms, Binney brings over two decades of commercial leadership experience that will be instrumental to SetPoint's mission to deliver a new treatment alternative to patients with autoimmune conditions, including rheumatoid arthritis (RA). "Tyler has a strong track record of building successful commercial organizations and delivering sustained growth in new markets," said Murthy V. Simhambhatla, Ph.D., Chief Executive Officer of SetPoint Medical. "His experience bringing novel, category-creating technologies to market will be an incredible asset to our team as we work to provide patients with access to our innovative neuroimmune modulation platform." With over 20 years of proven leadership experience in the medical device industry, Mr. Binney most recently served as President and Chief Executive Officer of Relievant Medical Systems, which Boston Scientific acquired in November 2023 for an upfront payment of $850 million, plus performance-based earnouts. Previously, he served as President and General Manager of the Interventional Urology Business Unit at Teleflex, and as Vice President of Sales at NeoTract, where he led the successful commercialization of the UroLift® System, contributing to its $1.1 billion acquisition by Teleflex. "What SetPoint is doing in the field of neuroimmune modulation is truly groundbreaking," said Tyler Binney. "This team is on the verge of transforming the treatment of chronic autoimmune conditions, and I look forward to contributing my experience as they accelerate their strategy to commercialize this platform technology." About SetPoint Medical SetPoint Medical is a privately held clinical-stage healthcare company dedicated to treating people living with chronic autoimmune diseases. The company is developing a novel platform designed to stimulate the vagus nerve to activate neuroimmune pathways to produce a systemic anti-inflammatory and immune-restorative effect. SetPoint Medical's platform technology is designed to offer patients and providers a treatment alternative for rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and other chronic autoimmune conditions with potentially less risk and cost than drug therapy. For more information, visit View source version on Contacts Emma YangHealth+Commercemedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
